Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500362 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL596961 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL22103542 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL25602753 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL7763250 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL31621964 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL6256125 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL596960 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29424947 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL596962 | 0.98 | CHRM2 (0.44) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | ABBVIE INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8497275-B2 | HCV protease inhibitors and uses thereof | ABBVIE INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7893296-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7084178-B2 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| WO-2005054180-A1 | ANTIAMYLOID PHENYLSULFONAMIDES: N-CYCLOALKYLCARBOXAMIDES DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050113442-A1 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-26 | — | — | US | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | disclosed |
| EP-1299379-A2 | LACTAM METALLOPROTEASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002004416-A2 | LACTAM METALLOPROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | CHRM2 392/4885CHRM4 267/4885CHRM3 602/4885 |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | CYP1B1, CYP2E1, DAZAP1 | CHRM2 3100/4885CHRM4 2550/4885CHRM3 2542/4885 |
| US-20130303547-A1 | HCV Protease Inhibitors and Uses Thereof | SERPINB1, PEPD, PREP | CHRM2 4881/4885CHRM4 4874/4885CHRM3 4860/4885 |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | CHRM2 4065/4885CHRM4 4558/4885CHRM3 4387/4885 |
| US-20050113442-A1 | Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives | APP, PSEN1, PSEN2 | CHRM2 1452/4885CHRM4 1694/4885CHRM3 1943/4885 |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | THOP1, XDH, DUOX1 | CHRM2 2808/4885CHRM4 4333/4885CHRM3 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.